Personalized Tumor Vaccine Hits Phase 2

New Drug Approvals

Bevacizumab

bevacizumab

str ref———-http://www.kidneycancerinstitute.com/Bevacizumab.html

Northwestern Medicine recently joined a landmark clinical trial to investigate if a vaccine made from a patient’s own brain tumor is effective in slowing tumor progression and extending survival. The randomized phase 2 trial will study how well giving the study vaccine with or without Avastin (bevacizumab) works in treating patients with recurrent glioblastoma multiforme (GBM).

http://www.dddmag.com/news/2013/08/personalized-tumor-vaccine-hits-phase-2?et_cid=3425506&et_rid=523035093&type=cta

 

Bevacizumab
(Avastin, Genentech Inc.- Year approved:2009)
Avastin (or bevacizumab to the scientific community) is a humanised monoclonal antibody that is directed against all biologically active forms of VEGF. Antibodies are molecules that are typically a normal part of the human immune system. An antibody is meant to bind to a very specific target which is then typically destroyed and removed by the body. Avastin is an antibody that binds VEGF and acts to block its action.
Bevacizumab was one of the first antiangiogenic agents to demonstrate activity against…

View original post 607 more words

Advertisements

Alnylam Hemophilia Drug Garners Orphan Drug Status

New Drug Approvals

CAMBRIDGE, Mass., Aug 14, 2013 (AP) — The Food and Drug Administration has granted an “orphan drug designation” to a potential hemophilia treatment from Alnylam Pharmaceuticals Inc.

Orphan drug status is awarded to drugs that could treat diseases that affect fewer than 200,000 people in the United States. It comes with some added marketing exclusivity.

The Cambridge, Mass., company said Wednesday that the agency gave the designation to a drug labeled ALN-AT3 for the treatment of hemophilia B. Alnylam has tested the drug in mice and plans to start studies involving humans early next year.

for the treatment of hemophilia B. Alnylam has tested the drug in mice and plans to start studies involving humans early next year.

http://www.pharmalive.com/alnylam-hemophilia-drug-garners-orphan-drug-status

 

View original post

Propecia Could Save 70,000 Men From Prostate Cancer

New Drug Approvals

File:Finasteride.svg

finasteride

The baldness drug propecia could help reduce the risk of prostate cancer with less side-effects than previously thought, according to a new study.

By Amir Khan, Everyday Health Staff Writer

Warding off prostate cancer may be as easy as growing your hair, according to new data published in the New England Journal of Medicine by researchers from the University of Texas Health Science Center at San Antonio. The researchers followed up on patients from one of their previous studies, and found that the baldness drug finasteride, also known as Propecia, reduced the risk of prostate cancer by more than a third, and resulted in less-severe side effects than previously thought.

“If you look at the number of prostate cancers that are diagnosed annually and multiply that by 30 percent, that’s the number of cancers we might be able to prevent each year,” Ian Thompson Jr., MD, study author and director…

View original post 188 more words

Coming soon – The Peoples Voice TV – Mainstream Media becoming irrelevant?

nuclear-news

Published on 31 May 2013

Click here for more information and to donate: http://igg.me/at/davidicke

The people are stirring and the lion is preparing to roar
This is its microphone…

This entry was posted on July 17, 2013.

We have 30 days from today to raise the money that will put this TV and Radio station on air within months to expose the information across multiple subjects that the mainstream media will not cover and to give a voice to the currently voiceless all over the world.

Let us put aside that which divides us and come together as One Global Human Voice – The People’s Voice.

ENOUGH – we are not taking this shit anymore!

The people can have a voice that brings us together and bypasses mainstream censorship all over the world – but we need your help to make this happen within months.

Click here for more…

View original post 5 more words

J and J gets green light for front-line Velcade in EU

New Drug Approvals

Bortezomib

Johnson & Johnson’s multiple myeloma treatment Velcade has been cleared as a first-line therapy in the EU, boosting the number of patients eligible for treatment with the drug.

The European Commission gave the go-ahead for Velcade (bortezomib) as induction therapy in combination with dexamethasone and thalidomide in previously-untreated multiple myeloma patients who are eligible for high-dose chemotherapy and a stem cell transplant.

http://www.pharmatimes.com/Article/13-08-09/J_J_gets_green_light_for_front-line_Velcade_in_EU.aspx

Bortezomib bound to the core particle in a yeast proteasome. The bortezomib molecule is in the center colored by atom type (boron = pink, carbon = cyan, nitrogen = blue, oxygen = red), surrounded by the local protein surface. The blue patch is catalyticthreonine residue whose activity is blocked by the presence of bortezomib.

Bortezomib (INN, originally codenamed PS-341; marketed as Velcade by Millennium Pharmaceuticals and Bortecad by Cadila Healthcare) is the first therapeutic proteasome inhibitor to be tested in humans…

View original post 278 more words

FDA APPROVED PRODUCT FOR PREMATURE EJACULATION

New Drug Approvals

 

VISIT

http://www.promescent.com/

<$3 per use for most men!!

In my practice this product
benefits both men and women by
helping a man have staying power
Felice Dunas, Ph.D., Sex Educator and Coach

…a significant delay in
ejaculation and an improved
sex life. It is easy, and it works.
Michael Chancellor, MD, Director of Neurourology Program

 

View original post

Ixchelsis, a start-up company that has come out of Pfizer’s former R D site at Sandwich, UK, is progressing a treatment for premature ejaculation boosted by the backing of Eli Lilly.

New Drug Approvals

 

Lilly, through its venture fund set up with TVM Capital Life Science, has
invested in Ixchelsis, made up of former Pfizer scientists and headed by Gary
Muirhead. The company is based on an oxytocin receptor antagonist called IX-01
originally discovered at Sandwich which the investors say “has the potential to
be the best-in-class pharmacological approach for the treatment of
PE”.

Ixchelsis, which is based at the Sandwich site, now called Discovery
Park, will collaborate with the autonomous early phase virtual drug discovery
arm of Lilly, known as Chorus. Dr Muirhead told PharmaTimes that the
TVM model will fund through to the agreed exit point, which is completion of
proof-of-concept and this requires about $14 million.

read all at

http://www.pharmatimes.com/Article/13-08-08/Lilly_backs_Ixchelsis_a_start-up_born_at_Pfizer.aspx

………..

………….

……………….

…………….

View original post